Hurel® Corporation Completes Investment from Johnston Associates
News Oct 08, 2014
Hurel Corporation has announced that Johnston Associates, Inc. of Princeton, New Jersey (“JAI”) has become a participating investor in the Company’s Series A-3 Preferred Stock financing. Hurel’s lead private equity investor, Spring Mountain Capital, LP, of New York, led the A-3 round.
“Johnston Associates is pleased to invest in Hurel, which is about to emerge as the leader in cell-based liver models,” Robert F. Johnston, JAI’s Managing Partner, said. “Hurel’s products have the capacity to improve and ultimately transform how preclinical drug discovery and general chemical testing are carried out. I’m looking forward to working with Hurel’s talented management team as they extend the commercial reach of their products and their company.”
Hurel CEO Robert Freedman commented, “As a founder of multiple, major biotech companies, Bob Johnston brings Hurel an immense resource of knowledge upon which we will be able to draw. It’s an honor and a pleasure to welcome Bob to Hurel’s investor family.”
Bioengineered Robotic Hand With Its Own Nervous System Will Sense TouchNews
A team of scientists from Florida Atlantic University are developing a first-of-its-kind bioengineered robotic hand that will grow and adapt to its environment.READ MORE
Rap Parody Wins the MicroTAS Video Competition 2017News
First prize awarded to two PhD candidates from Johns Hopkins University in Baltimore, Maryland.READ MORE
Joining Forces to Develop “Nephron-on-a-Chip" to Accelerate Drug Discovery in Kidney DiseaseNews
A new consortium to accelerate the discovery of novel drugs to treat kidney diseases was announced Monday 6 November. The NEPLEX (nephron on a chip with cellular and extracellular matrix complexity) consortium will combine key technologies to develop and build a novel drug discovery device ("Nephron-on-a-Chip").